Kezar Life Sciences (NASDAQ:KZR) Releases Earnings Results, Misses Estimates By $0.60 EPS

Kezar Life Sciences (NASDAQ:KZR) released its earnings results on Friday. The company reported ($1.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.60), FiscalAI reports.

Kezar Life Sciences Stock Down 2.4%

KZR traded down $0.15 on Friday, reaching $6.20. The company’s stock had a trading volume of 27,253 shares, compared to its average volume of 37,123. Kezar Life Sciences has a 1 year low of $3.53 and a 1 year high of $7.45. The business’s 50 day moving average is $6.52 and its 200 day moving average is $5.87. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.07 and a quick ratio of 7.06. The stock has a market cap of $45.40 million, a price-to-earnings ratio of -0.73 and a beta of 0.53.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kezar Life Sciences in a report on Monday, December 22nd. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Kezar Life Sciences presently has an average rating of “Reduce” and a consensus target price of $6.00.

Institutional Trading of Kezar Life Sciences

Several institutional investors have recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. bought a new stake in Kezar Life Sciences in the third quarter valued at $51,000. Torno Capital LLC bought a new stake in shares of Kezar Life Sciences during the fourth quarter valued at approximately $126,000. Woodline Partners LP bought a new position in Kezar Life Sciences in the 1st quarter worth approximately $125,000. Dimensional Fund Advisors LP boosted its position in Kezar Life Sciences by 14.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock worth $167,000 after acquiring an additional 3,312 shares during the period. Finally, State Street Corp increased its holdings in shares of Kezar Life Sciences by 28.4% during the fourth quarter. State Street Corp now owns 27,093 shares of the company’s stock valued at $170,000 after purchasing an additional 6,000 shares during the period. 67.90% of the stock is owned by institutional investors and hedge funds.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.